95%Confidence
0Views
FDASource
2026-04-14Date
Summary
A third Class II recall for Teva's Octreotide Acetate (30 mg) confirms widespread sterility failures at the contract manufacturer, signaling severe quality system breakdowns. This may trigger FDA enforcement actions and necessitate finding new manufacturing partners, increasing operational costs.
Actionable: Consider reducing exposure to Teva until remediation plans are clear.
AI Confidence: 95%
Data Points
firmTeva Pharmaceuticals USA, Inc
classificationClass II
statusOngoing
distributionNationwide in the USA
productOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, Single-dose 8 mL vial, Rx only, Manufactured in Greece BY: Pharmat
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now